These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3747258)

  • 21. A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson's disease.
    Corona T; Rivera C; Otero E; Stopp L
    Clin Neuropharmacol; 1995 Aug; 18(4):325-32. PubMed ID: 8665545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levodopa Is a Double-Edged Sword for Balance and Gait in People With Parkinson's Disease.
    Curtze C; Nutt JG; Carlson-Kuhta P; Mancini M; Horak FB
    Mov Disord; 2015 Sep; 30(10):1361-70. PubMed ID: 26095928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The long-term results of stereotaxic surgery and L-dopa therapy in patients with Parkinson's disease. A 10-year follow-up study.
    Kelly PJ; Gillingham FJ
    J Neurosurg; 1980 Sep; 53(3):332-7. PubMed ID: 6999132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alpha-dihydroergocryptine in the long-term therapy of Parkinson's disease.
    Mailland E; Magnani P; Ottillinger B
    Arzneimittelforschung; 2004; 54(10):647-54. PubMed ID: 15553103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease.
    Reichmann H; Brecht MH; Köster J; Kraus PH; Lemke MR
    CNS Drugs; 2003; 17(13):965-73. PubMed ID: 14533946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing Parkinson's disease with continuous dopaminergic stimulation.
    Wolters E; Lees AJ; Volkmann J; van Laar T; Hovestadt A
    CNS Spectr; 2008 Apr; 13(4 Suppl 7):1-14; quiz 15-6. PubMed ID: 18408654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of early dopa treatment in Parkinson's disease.
    Markham CH; Diamond SG
    Ann Neurol; 1986 Apr; 19(4):365-72. PubMed ID: 3707088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?
    Bonnet AM; Loria Y; Saint-Hilaire MH; Lhermitte F; Agid Y
    Neurology; 1987 Sep; 37(9):1539-42. PubMed ID: 3627454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variability in spatiotemporal gait characteristics over the course of the L-dopa cycle in people with advanced Parkinson disease .
    MacKay-Lyons M
    Phys Ther; 1998 Oct; 78(10):1083-94. PubMed ID: 9781702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical criteria for the switch of treatment strategies in Parkinson's disease.
    Schoenfeld MA; Pantelie CM; Schwartz B
    Clin Neurol Neurosurg; 2003 Sep; 105(4):241-4. PubMed ID: 12954538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Outcome of Parkinsonism after two years of levodopa plus R04-4602 (author's transl)].
    Faglioni P; Gasparini M; Spinnler H
    Riv Patol Nerv Ment; 1975; 96(4):270-86. PubMed ID: 785578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disordered axial movement in Parkinson's disease.
    Steiger MJ; Thompson PD; Marsden CD
    J Neurol Neurosurg Psychiatry; 1996 Dec; 61(6):645-8. PubMed ID: 8971118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy.
    Mones RJ
    J Neurol Neurosurg Psychiatry; 1973 Jun; 36(3):362-7. PubMed ID: 4714098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.
    Fabbri M; Pongmala C; Artusi CA; Romagnolo A; Rizzone MG; Zibetti M; Lopiano L
    Acta Neurol Scand; 2019 Aug; 140(2):157-161. PubMed ID: 31025312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.